Analyst Ratings for Keros Therapeutics (KROS)
KROS Rating Summary
KROS Price Target Summary
- Highest: $27.00 (Oppenheimer)
- Lowest: $19.00 (BofA Securities)
- Average: $21.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$21.50 (+90.3%)
* Over Last 12-Mos
Rating Score: 5.3 / 10
Percentile Rank: 57%
Avg. $ Target:
$21.50 (+90.3%)
* Over Last 12-Mos
Rating Score: 5.3 / 10
Percentile Rank: 57%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/19/2025 | TD Cowen | Nick Lorusso | New Coverage | Hold (N/A) |
N/A (N/A) |
20.83 (11.30) |
-45.75% | Details |
| 10/20/2025 | Wells Fargo » Updated 3/5/2026 |
Ben Burnett | New Coverage | Overweight (N/A) |
20.00 (23.00) |
13.83 (11.30) |
-18.29% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
